Quince Therapeutics, Inc. (QNCX)
(Delayed Data from NSDQ)
$1.70 USD
+0.16 (10.39%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $1.62 -0.08 (-4.71%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
QNCX 1.70 +0.16(10.39%)
Will QNCX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for QNCX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QNCX
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
QNCX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for QNCX
Quince Therapeutics initiated with bullish view at Maxim
This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Quince Therapeutics initiated with a Buy at Rodman & Renshaw
Quince Therapeutics initiated with bullish view at Rodman & Renshaw
12 Health Care Stocks Moving In Friday's Pre-Market Session